Newsletter
Newsletter Support JNS

Gantz: Israel to begin human trials on COVID-19 vaccine in September

“You are Israel’s special forces when it comes to vaccines,” Defense Minister Benny Gantz tells Israel Institute for Biological Research staff.

Israeli Defense Minister Benny Gantz pays a visit to Leah and Simcha Goldin, parents of fallen IDF soldier Lt. Hadar Goldin, as they attend a passive protest outside the military cemetery in Jerusalem on July 2, 2020. Photo by Olivier Fitoussi/Flash90.
Israeli Defense Minister Benny Gantz pays a visit to Leah and Simcha Goldin, parents of fallen IDF soldier Lt. Hadar Goldin, as they attend a passive protest outside the military cemetery in Jerusalem on July 2, 2020. Photo by Olivier Fitoussi/Flash90.

Israeli Defense Minister Benny Gantz said on Thursday that the Jewish state will soon begin human trials on a potential COVID-19 vaccine.

Gantz, who visited the Israel Institute for Biological Research earlier in the day to monitor the early stages of the vaccine’s development, said a group of Israelis will start getting shots after the High Holidays in September.

The institute, which is run under the auspices of the Defense Ministry, has recently said it has had promising results in lab testing for a potential vaccine. Some of those findings were shown to Gantz on Thursday.

According to Israel Hayom, the vaccine’s production line will be in Israel, but the antibody production, which is less sophisticated, will be carried out abroad due to high costs.

“Just like the Israel Defense Forces has special units that go behind enemy lines to clear the way forward, you are Israel’s special forces when it comes to vaccines,” Gantz told the institute’s staff.

The first phase of the human clinical trial will look to evaluate its safety.

The second phase, which may get a green light even as the first phase is being carried out, will determine its effectiveness on a small sample, with the final stage involving widespread injections on a large group of people, while observing a control group, to determine its overall impact in fending off the disease among the population.

This article first appeared in Israel Hayom.

“Jews make up a small fraction of San Francisco’s population, yet anti-Jewish bias accounted for nearly half of all hate crimes reported so far this year,” Marc Levine, of the ADL, told JNS.
Board of Peace envoy Nickolay Mladenov denies claims of a financial deal with the terror group.
Jonathan Sarna, of Brandeis University, told JNS that the partnership “vividly displays the benefits of the free marketplace of competing synagogues in the American setting.”
The meeting “focused on strategies to strengthen Jewish safety and belonging, maintain candid lines of communication and collaborate on issues where we have shared values and goals,” Phylisa Wisdom, executive director of the Mayor’s office to Combat Antisemitism, told JNS.